The Pharmaceutical Market: Czech Republic

Date: January 31, 2013
Pages: 90
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P5559F216EBEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Czech Republic
OVERVIEW OF THE PHARMACEUTICAL MARKET IN CZECH REPUBLIC

The recent measures proposed by the Czech Republic's Ministry of Health will, in all likelihood, negatively affect the Czech pharmaceutical market. The introduction of reimbursement ceilings, blind bidding auctions and preferential prescribing will squeeze drugmakers' margins and shift some of the burden of healthcare spending onto the private sector. The outcome of similar measures in Hungary and Poland strongly supports our view that the business environment for drugmakers will worsen if these proposals are adopted. It is patients who, ultimately, will suffer.

Headline Expenditure Projections

Pharmaceuticals: CZK80.71bn (US$4.56bn) in 2011 to CZK79.76bn (US$4.2bn) in 2012; -1.2% in local currency terms and -7.1% in US dollar terms.

Healthcare: CZK298.49bn (US$16.88bn) in 2011 to CZK297.87bn (US$15.831bn) in 2012; +0.4% in local currency terms and -8.4% in US dollar terms.

Medical Devices: CZK26.51n (US$1.50bn) in 2011 to CZK26.91bn (US$1.43bn) in 2012; +1.5% in local currency terms and -4.6% in US dollar terms. Forecast moderat ely down due to macroeconomic factors.

Risk/Reward Rating: The Czech Republic retains its leading position in the CEE RRRs in Q113, after displacing Poland in our Q412 assessment. Despite leading in our regional RRR table, the outlook for growth for the Czech pharmaceutical market is not particularly robust, as a result of pricing pressure, impeded market entry and increasing generic substitution. An increase in VAT and a stringent reference pricing system have affected sales and hit manufacturers' margins respectively.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Czech Republic Pharmaceuticals And Healthcare Industry SWOT
    Czech Republic Political SWOT
    Czech Republic Economic SWOT
    Czech Republic Business Environment SWOT

PHARMACEUTICALS RISK/REWARD RATINGS

    Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113
    Rewards
    Risks

CZECH REPUBLIC – MARKET SUMMARY

REGULATORY REGIME

    Intellectual Property Environment
    Prescribing Rules
    Pharmaceutical Advertising
    Pricing Regime
    Reimbursement Regime
    Recent Pricing And Reimbursement Developments
    Changes To VAT
    Table: European VAT Rates On Medicines (%)

INDUSTRY DEVELOPMENTS

    Epidemiology
    Healthcare Sector
    Healthcare Insurance
    Healthcare Reforms
    Hospital Sector
    Research & Development Sector
    Clinical Trials
    Medical Devices

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Czech Pharmaceutical Sales, Historical Data and Forecasts
    Key Growth Factors – Industry
    Table: Czech Healthcare Expenditure Trends, Historical Data and Forecasts
    Table: Czech Government Healthcare Expenditure Trends, Historical Data and Forecasts
    Key Growth Factors – Macroeconomic
    Table: Czech Republic - Economic Activity

PRESCRIPTION DRUG MARKET FORECAST

      Table: Czech Prescription Drug Market Indicators, Historical Data and Forecasts
      Patented Drug Market Forecast
      Table: Czech Patented Drug Market Indicators, Historical Data and Forecasts
      Generic Drug Market Forecast
      Table: Czech Generics Drug Market Indicators, Historical Data and Forecasts
      OTC Medicine Market Forecast
      Table: Czech Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
      Pharmaceutical Trade Forecast
      Table: Czech Pharmaceutical Trade Data And Forecasts (US$mn)
      Table: Czech Pharmaceutical Trade Data And Forecasts (CZKmn)
      Medical Device Market Forecast
      Table: Czech Medical Device Market Indicators, Historical Data and Forecasts
      Other Healthcare Data Forecasts
      Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Sector
      Foreign Pharmaceutical Players
      Company Developments
      Pharmaceutical Wholesale
      Pharmaceutical Retail
      Table: Retail Pharmacy Market Overview, 2004-2010
      Pharmaceutical Distribution Developments
      Distance Selling Of Pharmaceuticals

COMPANY PROFILES

  Local Companies
      Zentiva (Sanofi)
      Walmark
  Multinational Companies
      AstraZeneca
      Bristol-Myers Squibb
      Sanofi
      Novartis
      GlaxoSmithKline
      Pfizer

DEMOGRAPHIC OUTLOOK

      Table: Czech Republic’s Population By Age Group, 1990-2020 (‘000)
      Table: Czech Republic’s Population By Age Group, 1990-2020 (% of total)
      Table: Czech Republic’s Key Population Ratios, 1990-2020
      Table: Czech Republic’s Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

HOW WE GENERATE OUR PHARMACEUTICAL INDUSTRY FORECASTS

PHARMACEUTICALS RISK/REWARD RATINGS METHODOLOGY

RATINGS OVERVIEW

TABLE: PHARMACEUTICAL BUSINESS ENVIRONMENT INDICATORS

WEIGHTING

TABLE: WEIGHTING OF COMPONENTS

SOURCES
Skip to top


Ask Your Question

The Pharmaceutical Market: Czech Republic
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: